Endocrinology
News
Treatment of heart failure with preserved ejection fraction is a work in progress
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care...
News
Farxiga granted Priority Review for treatment of adults with HFrEF
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults...
News
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
News
Findings confirm link between methimazole and risk for acute pancreatitis
CHICAGO – However, there is no evidence of a cumulative dose effect.
Video
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
PHILADELPHIA –
From the Society
Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital
The tools available in the GC eQUIPS program are powerful for data analysis and benchmarking.
News
New model for CKD risk draws on clinical, demographic factors
The equation has demonstrated high discrimination and variable calibration across a range of populations.
News
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
News
Certain diabetes drugs may thwart dementia
COPENHAGEN – Intriguing findings from a Danish national registry study.